MEDIGENE AG - DE000A40ESG2 (Stock)
XETRA
| Price | Diff.% | Date & Time | Bid volume | Bid | Ask | Ask volume |
|---|---|---|---|---|---|---|
0,1995 EUR
|
15,3179% | 17.04.2025 17:36 | - | - | - | - |
| Contact | |
|---|---|
|
|
MediGene AG Lochhamer Strasse 11, Planegg 82152, Martinsried, DE |
| Phone | +49-89-20-00-33-0 |
| Fax | +49-89-20-00-33-29-20 |
| info@medigene.com | |
| Internet | http://www.medigene.de |
| IR Contact/PR Contact | -/- |
| Symbol | MDG2 |
| End of financial year | 31.12.2025 |
| Issued capital | 2.754.204,89 EUR |
| Shareholders | |
|---|---|
| Freefloat | 96,81% |
| Dolores J. Schendel | 2,84% |
| Dimensional Fund Advisors LP | 0,14% |
| Selwyn Ho | 0,10% |
| Frank Matthias | 0,07% |
| Santander Towarzystwo Funduszy Inwestycyjnych SA | 0,03% |
| Axel-Sven Malkomes | 0,00% |
| Board | |
|---|---|
| Dr. Selwyn Ho | Chairman of Managing Board |
| Dr. Dr. Dolores J. Schendel | Member of Executive Committee |
| Dr. Gerd Zettlmeissl | Chairman of Supervisory Board |
| Antoinette Hiebeler-Hasner | Member of Supervisory Board |
| Dr. Frank Mathias | Member of Supervisory Board |
| Dr. Anthony Man | Member of Supervisory Board |
| Ronald Scott | Member of Supervisory Board |
| Activity Description |
|---|
|
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany. |
© 2000 - 2025 UniCredit Bank Austria AG. Please read our terms and conditions
Implemented and powered by FactSet
Fond data is provided from Mountain-View Data Gmbh
Austria-HomePage Version 2.0.54
